Compare Petróleo Brasileiro SA (PBR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs TG Therapeutics Inc — how do they compare? Petróleo Brasileiro SA trades at $25.33 (market cap $151.94B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Petróleo Brasileiro SA is far larger — about 18.6× TG Therapeutics Inc's market cap, and Petróleo Brasileiro SA pays a 6.79% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 25 Days and TG Therapeutics Inc for 16 Days on average.
| PBR | TGTX | |
|---|---|---|
Market Cap | $151.94B | $8.16B |
Volume | 30,240,092 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $24.69 | $59.06 |
52-Week Low | $11.54 | $26.94 |
Typical Hold Time | 25 Days | 16 Days |
Enterprise Value | $212.36B | $8.37B |
Dividend Yield | 6.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) trades at $25.41, up 5.92% in 24 hours, reflecting strong momentum. The stock shows robust fundamentals with a P/E of 6.24 and net income margin of 24.52%, supported by recent earnings beats. Technical indicators signal a bullish trend, though RSI levels suggest potential overbought conditions. Positive news includes a new oil discovery off Amapa and a 22-year LNG deal with Cheniere Energy, highlighting growth prospects.
The outlook for PBR is favorable due to solid profitability, expansion projects, and analyst consensus leaning buy. Key risks involve political interference in Brazil, volatile oil prices, and high debt levels. Investors should weigh strong cash flows against geopolitical and commodity cycle exposures for balanced decision-making.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
